Science Explorer Interactive view Map
Company · Roscoff · France

ManRos Therapeutics (France)

manros-therapeutics.comROR OpenAlex
Research works
53
▼ 56% vs 2013–17
Citations
1.3k
25.2 per fractional work
Top-10% rate
34.9%
record average 16.5%
Open access
54%
world 28%

Not ranked overall: ManRos Therapeutics (France) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.99× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 2.80× its world share, 0 worksImmunology and Micro…Neuroscience: 0.04× its world share, 0 worksNeuroscienceComputer Science: 0.40× its world share, 0 worksComputer ScienceEngineering: 0.06× its world share, 0 worksEngineeringMathematics: 2.66× its world share, 0 worksMathematicsHealth Professions: 1.49× its world share, 0 worksHealth ProfessionsMedicine: 3.16× its world share, 6 worksMedicineDecision Sciences: 4.05× its world share, 0 worksDecision Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Decision Sciences, 4.0×. Every wedge is a field page.

Which keywords describe research at ManRos Therapeutics (France)?

By fractional works in all years, weighted toward what it does more of than the world: Quality of Life, Cancer Therapy, Synthesis, Apoptosis, Prevalence, Down Syndrome, Intellectual Disability and Mental Health.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Quality of Life5▲ 6.6×12 topics
  2. Cancer Therapy4▲ 13×8 topics
  3. Synthesis4▲ 12×11 topics
  4. Mental Health3▲ 5.7×3 topics
  5. Apoptosis3▲ 16×7 topics
  6. Prevalence3▲ 15×3 topics
  7. Down Syndrome3▲ 663×1 topic
  8. Intellectual Disability3▲ 314×1 topic
  9. Epidemiology3▲ 1.34×25 topics
  10. Biological Evaluation3▲ 43×5 topics
  11. CFTR3▲ 180×1 topic
  12. Cystic Fibrosis3▲ 61×2 topics
  13. Pulmonary Infections3▲ 88×1 topic
  14. Anticancer2▲ 22×5 topics
  15. Anticancer Agents2▲ 17×7 topics
  16. Medicinal Chemistry2▲ 11×4 topics
  17. Regulation2▲ 6.4×3 topics
  18. Mutation2▲ 24×3 topics
  19. Heterocyclic Compounds2▲ 23×3 topics
  20. Tumor Suppression2▲ 31×2 topics
  21. Antimicrobial2▲ 13×4 topics
  22. Cell Cycle2▲ 60×1 topic
  23. p532▲ 80×1 topic
  24. Antimicrobial Activity2▲ 16×3 topics
  25. Molecular Docking2▲ 21×3 topics
  26. Therapeutic Targets2▲ 13×4 topics
  27. Drug Discovery1▲ 6.8×4 topics
  28. Pharmacology1▲ 8.2×5 topics
  29. Prognostic Factors1▲ 5.6×5 topics
  30. Neurodegeneration1▲ 7.9×5 topics
  31. Alkaloids1▲ 31×3 topics
  32. Cell Signaling1▲ 7.0×3 topics
  33. Chronic Lymphocytic Leukemia1▲ 41×1 topic
  34. Content-Based Image Retrieval1▲ 42×1 topic
  35. Financial Regulation1▲ 135×1 topic
  36. Genomic Aberrations1▲ 41×1 topic
  37. Global Governance1▲ 8.6×1 topic
  38. Marine Natural Products1▲ 33×2 topics
  39. Shape Matching1▲ 42×1 topic
  40. Transcriptional Regulation1▲ 7.8×3 topics

Which research topics does ManRos Therapeutics (France) publish most on?

By volume in 2022–2025: Down syndrome and intellectual disability research, Cystic Fibrosis Research Advances, Alzheimer's disease research and treatments and Neonatal Respiratory Health Research.

Down syndrome and intell…2Down syndrome and intellectual disability research: 2 fractional worksCystic Fibrosis Research Advances: 1 fractional worksAlzheimer's disease research and treatments: 1 fractional worksNeonatal Respiratory Health Research: 0 fractional worksRetinoids in leukemia and cellular processes: 0 fractional worksOptimal Experimental Design Methods: 0 fractional worksVascular Anomalies and Treatments: 0 fractional worksBiological Research and Disease Studies: 0 fractional worksDrug-Induced Ocular Toxicity: 0 fractional worksStatistical Methods in Clinical Trials: 0 fractional works
Public Health, Environmental and Occupational HealthPulmonary and Respiratory MedicinePhysiologyMolecular Biology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Down syndrome and intellectual disability research Public Health, Environmental and Occupational Health 2 works
  2. 2 Cystic Fibrosis Research Advances Pulmonary and Respiratory Medicine 1 works
  3. 3 Alzheimer's disease research and treatments Physiology 1 works
  4. 4 Neonatal Respiratory Health Research Pulmonary and Respiratory Medicine 0 works
  5. 5 Retinoids in leukemia and cellular processes Molecular Biology 0 works
  6. 6 Optimal Experimental Design Methods Management Science and Operations Research 0 works
  7. 7 Vascular Anomalies and Treatments Genetics 0 works
  8. 8 Biological Research and Disease Studies Molecular Biology 0 works
  9. 9 Drug-Induced Ocular Toxicity Ophthalmology 0 works
  10. 10 Statistical Methods in Clinical Trials Statistics and Probability 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available53.9%not open46.1%

World: 28% of research is openly available.

with international co-authors38.5%domestic only61.5%

World: 19% is written across borders.

How has ManRos Therapeutics (France)'s research output changed?

Output in 2018–2022 was 56% lower than in 2013–2017.

200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Roscoff

All research institutions in Roscoff

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.